Vadastuximab talirine: Additional Phase I data

Data from 49 evaluable newly diagnosed patients with CD33-positive AML in an open-label, U.S. Phase I trial showed that IV vadastuximab talirine plus Vidaza azacitidine or decitabine led to an overal...